Latest / Stock Movers / Novo Nordisk's Discount, Pernod Ricard Dips, Next Jitters
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio news.
- 0:08Speaker 2: The Stock Movers Report, your roundup of companies making moves
- 0:12Speaker 2: in the stock market, harnessing the power of Bloomberg data.
- 0:16Speaker 3: Let's take a look at some stocks on move today.
- 0:18Speaker 3: I'm Tom McKenzie alongside Corn Heca. Of course, we're joined
- 0:21Speaker 3: now by Bloomberg reporter Chloe Malay. Chloe. Novo in focus,
- 0:25Speaker 3: of course, the drug maker and the maker of weight
- 0:26Speaker 3: loss drugs, but not necessarily for good reason. What's going
- 0:31Speaker 3: on with the stock?
- 0:32Speaker 1: Yeah, so the US government negotiated a seventy one percent
- 0:35Speaker 1: at discount on the price of both azempic and wigov
- 0:38Speaker 1: which of course are two of Novo's a blockbuster drugs,
- 0:41Speaker 1: So it now prices them at two hundred and seventy
- 0:43Speaker 1: four dollars a month for patients on Medicare, which is
- 0:45Speaker 1: the health insurance program for the elderly and the disabled
- 0:49Speaker 1: in the US. Nova said that it actually remained opposed
- 0:52Speaker 1: to that government price setting. But it actually seems that
- 0:55Speaker 1: investors are not two phased by the news. They say
- 0:57Speaker 1: that this is kind of mostly priced in the This
- 1:00Speaker 1: is part of all of the drug pricing negotiations with
- 1:03Speaker 1: the pharmaceutical industry that was conducted by the Trump administration,
- 1:07Speaker 1: of course, using tariffs, using those regulatory threats to try
- 1:10Speaker 1: and reduce the cost of healthcare and boost local manufacturing
- 1:14Speaker 1: in the US, and the Trump administration said the new
- 1:17Speaker 1: prices would represent a twelve billion dollars in savings compared
- 1:20Speaker 1: with what Medicare had spent on those same drugs last year,
- 1:24Speaker 1: So that that's not only a zepic and MCGOVI, but
- 1:26Speaker 1: a range of other drugs that are seeing those Medicare cuts.
- 1:30Speaker 1: So although it sounds like actually quite a steep price cut,
- 1:33Speaker 1: analysts are saying that the impact will actually not be
- 1:35Speaker 1: too material for Novo and that explains the shares a
- 1:39Speaker 1: shrugging this.
- 1:39Speaker 4: Off mostly for that company.
- 1:41Speaker 5: Okay, so that on another Nordisk now Alice are looking
- 1:44Speaker 5: at alcohol, tobacco, but cautious on luxury. Is that a
- 1:49Speaker 5: Christmas list or is it a stopic?
- 1:51Speaker 4: Yeah?
- 1:51Speaker 1: So Panoga, which obvious the maker of spirits, It's down
- 1:55Speaker 1: this morning after being placed on a negative catalyst watch
- 1:58Speaker 1: by JP Morgan Alys.
- 2:00Speaker 4: So the analyst said that they were taking quite.
- 2:02Speaker 1: A cautious approach on the consumer staples sector in Europe
- 2:06Speaker 1: as a whole because of higher unemployment and lower consumer
- 2:09Speaker 1: confidence that will be probably weighing that sector down in
- 2:12Speaker 1: twenty twenty six. But within that they prefer some categories
- 2:15Speaker 1: over others, so cigarettes, for example, is better place, so
- 2:18Speaker 1: Imperial brands beer like with companies like Carsburg is better placed.
- 2:22Speaker 1: But unfortunately for Pano it doesn't fit within those categories.
- 2:26Speaker 1: It is a higher price point and therefore a bit
- 2:28Speaker 1: more exposed to that lower consumer confidence. Just a few
- 2:32Speaker 1: weeks ago it had to cut its outlook because it
- 2:34Speaker 1: had a very steep drop in sales and really weak
- 2:36Speaker 1: demand across all of its key markets, and it seems
- 2:40Speaker 1: that analysts don't believe that it'll be able to get
- 2:42Speaker 1: out of that slump anytime soon.
- 2:44Speaker 3: I'm talking you have consumer sentiment retailer next in focus
- 2:48Speaker 3: as well. How much of this is a litmus test.
- 2:51Speaker 4: Really as we lead up to the budget at twelve thirty.
- 2:54Speaker 1: Today, Yeah, it's really all about that those pre budget
- 2:57Speaker 1: jitters across the UK stop market, so they'll be obviously
- 3:00Speaker 1: focused throughout the day, But for now we can already
- 3:02Speaker 1: see some weakness in the shares of some retailers that
- 3:05Speaker 1: was obviously due to the announcement last night over hike
- 3:08Speaker 1: in the minimum wage, So that has an impact on
- 3:10Speaker 1: companies like Next, of course, but also supermarkets, high street chains, pubs,
- 3:15Speaker 1: et cetera, all of those companies that have really large
- 3:18Speaker 1: young workforces and therefore a minimum wage increase represents quite
- 3:22Speaker 1: a big hike in costs for them, and we can
- 3:24Speaker 1: see that reflected in the.
- 3:25Speaker 4: Shares in Next this morning.
- 3:28Speaker 1: The problem with the minimum wage hike, according to economists,
- 3:31Speaker 1: is that it's already among the highest globally, productivity is
- 3:35Speaker 1: meanwhile lagging behind other countries.
- 3:36Speaker 4: So it creates this imbalance that is quite.
- 3:39Speaker 1: Tough, quite challenging for both workers and employers, and that
- 3:43Speaker 1: is weighing down those retailers, those supermarkets this morning.
- 3:47Speaker 4: Let's see what we get later in the budget.
- 3:50Speaker 2: The Stock Movers report from Bloomberg Radio. Check back with
- 3:54Speaker 2: us throughout the day for the latest roundup of companies
- 3:57Speaker 2: making news on Wall Street and for the latest market
- 4:00Speaker 2: kid moving headlines. Listen to Bloomberg Radio Live, catch us
- 4:04Speaker 2: on YouTube, Bloomberg dot com, and on Applecarplay and Android
- 4:07Speaker 2: Auto with the Bloomberg Business app.